{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n", " from tqdm.autonotebook import tqdm, trange\n" ] } ], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re" ] }, { "cell_type": "code", "execution_count": 76, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]\n", "\n", "\n", "# Target列を分割する関数（改良後）\n", "def split_target_English(target):\n", " # 区切り文字を (,) or (\\n) or (、) or (・) または文字列\"or\" として扱う\n", " # 正規表現では、パイプ(|)でor条件を定義し、\"(?: ... )\"はグルーピングのみ行う非捕捉グループ\n", " # [,\\n、・] はいずれかの1文字とマッチ\n", " # or は文字列全体とマッチ\n", " # 複数連続した区切り文字をまとめて1回の分割として扱うために+(1回以上)とする\n", " split_words = re.split(r'(?:[,\\n、・]|or| and)+', target)\n", " \n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]\n", "\n", "# 処理プログラム\n", "def split_triple_negative_words(target_words):\n", " updated_words = []\n", " for word in target_words:\n", " if 'triple negative' in word.lower():\n", " # 'triple negative' の部分を追加\n", " updated_words.append('Triple Negative') # 大文字で統一して追加\n", " # 'triple negative' を除いた残りの部分を追加\n", " remaining = word.lower().replace('triple negative', '').strip()\n", " if remaining: # 残りの単語が存在する場合のみ追加\n", " updated_words.append(remaining.title().strip()) # 単語の先頭を大文字化\n", " else:\n", " updated_words.append(word.strip().title()) # 単語の先頭を大文字化\n", " return updated_words\n", "\n", "class WordProcessor:\n", " def __init__(self, target_words):\n", " self.target_words = target_words\n", "\n", " def process(self, target_words):\n", " \"\"\"\n", " 入力された単語のリストを処理して、ターゲット単語に基づき分割します。\n", " \"\"\"\n", " updated_words = []\n", " for word in target_words:\n", " word_lower = word.lower()\n", " for target in self.target_words:\n", " if target in word_lower:\n", " # ターゲット単語を追加\n", " updated_words.append(target.title())\n", " # ターゲット単語を除いた残りを追加\n", " remaining = word_lower.replace(target, '').strip()\n", " if remaining:\n", " updated_words.append(remaining.title())\n", " break\n", " else:\n", " # ターゲット単語に該当しない場合\n", " updated_words.append(word.strip().title())\n", " return updated_words\n", "\n", " def __call__(self, target_words):\n", " \"\"\"\n", " インスタンスを関数として呼び出すためのエントリポイント。\n", " \"\"\"\n", " return self.process(target_words)\n" ] }, { "cell_type": "code", "execution_count": 77, "metadata": {}, "outputs": [], "source": [ "exclusive_words = [\"triple negative\", \"double positive\"]\n", "\n", " # インスタンス作成\n", "processor = WordProcessor(exclusive_words)" ] }, { "cell_type": "code", "execution_count": 78, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)\n", "# 各行のTargetWord列に処理を適用\n", "# NaN や None の場合の処理を追加\n", "basedf['TargetWord'] = basedf['TargetWord'].apply(lambda x: processor(x) if isinstance(x, list) else x)" ] }, { "cell_type": "code", "execution_count": 79, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
0jRCT2031240552NCT06599502NaNKRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...Treatment1-2NaN...treatment purpose1. Participant must be 18 years or more, or th...1. Any significant laboratory finding or any s...18age old overNo limitBothNaNNaNAZD0022[Non-Small Cell Lung Cancer (Nsclc) Pancreatic...
3jRCT2031240547NaNNaNFGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...切除不能進行・再発の胃または食道胃接合部腺癌切除不能進行・再発の胃または食道胃接合部腺癌Advanced Gastric or Gastroesophageal Junction ...フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...2NaN...treatment purpose1) Histologically documented gastric or GEJ ad...1) Prior treatment with taxanes 2) Prior treat...18age old overNo limitBothNaNNaN- Bemarituzumab (15mg/kg, intravenous, Day1, 1...[Advanced Gastric, Gastroesophageal Junction C...
5jRCT2031240542NaNNaN自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...多発性骨髄腫多発性骨髄腫Multiple Myeloma自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...3NaN...treatment purpose1. Is at least 18 or the legal age of consent ...Participants are excluded from the study if an...18age old overNo limitBothNaNNaNArm A: Belantamab Mafodotin is intraveniously ...[Multiple Myeloma]
7jRCT2031240536NCT06003231NaN既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌Head and neck squamous cell carcinoma/Non-smal...既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...2NaN...treatment purposeCohort 1: Head and neck squamous cell carcinom...- Prior treatment with a monomethyl auristatin...18age old overNo limitBothNaNNaNExperimental Arm - Disitamab vedotin 1.5 mg/kg...[Head, Neck Squamous Cell Carcinoma/Non-Small ...
9jRCT2031240530NaNNaNHER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...Stage II-III HER2-Amplified or HER2-Mutant Non...HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...2NaN...treatment purpose1. Signed informed consent form 2. Age >= 18 y...1. NSCLC that is clinically T4 by virtue of me...18age old overNo limitBothNaNNaNThe study drug will be administered as an IV i...[Stage Ii-Iii Her2-Amplified, Her2-Mutant Non-...
..................................................................
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast Cancer]
739jRCT2073200004NaNNaN切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験膵癌膵癌Pancreatic cancer切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。1-2NaN...treatment purposeThe patients with pancreatic tumors must meet ...1) Patients with the following complications: ...20age old overNo limitBothNaNPancreatic ductal carcinoma, unresectableIntratumoral administration of oncolytic virus[Pancreatic Cancer]
760jRCT2033190086NaNNaN悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...悪性黒色腫悪性黒色腫malignant melanoma第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...1-2NaN...treatment purpose(Phase 1) 1) Histologically confirmed malignan...(Phase 1 and 2) 1) Patients who have brain and...20age old overNo limitBothNaNmalignamt melanoma, advanced stageTest drug (T-hIL12) will be administered into ...[Malignant Melanoma]
762jRCT2031190072NaNNaN切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験肝細胞癌肝細胞癌Hepatocellular carcinoma切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験1NaN...treatment purpose1) Histologically or cytologically confirmed h...1) CNS metastases that are symptomatic or requ...20age 0month 0week old overNo limitBothNaNCancer peptide vaccineReconstitute two kinds of cancer peptide vacci...[Hepatocellular Carcinoma]
772jRCT2051190009NCT03818893JapicCTI-194618進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...進行性悪性黒色腫進行性悪性黒色腫advanced melanoma抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...1-2NaN...treatment purposeInclusion criteria Patients meeting all of the...Exclusion criteria Patients meeting any of the...20age old over86age old notBothNaNadvanced melanomacombination therapy of intracutaneous GEN0101 ...[Advanced Melanoma]
\n", "

427 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "0 jRCT2031240552 NCT06599502 NaN \n", "3 jRCT2031240547 NaN NaN \n", "5 jRCT2031240542 NaN NaN \n", "7 jRCT2031240536 NCT06003231 NaN \n", "9 jRCT2031240530 NaN NaN \n", ".. ... ... ... \n", "729 jRCT2031200057 NaN NaN \n", "739 jRCT2073200004 NaN NaN \n", "760 jRCT2033190086 NaN NaN \n", "762 jRCT2031190072 NaN NaN \n", "772 jRCT2051190009 NCT03818893 JapicCTI-194618 \n", "\n", " Title \\\n", "0 KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併... \n", "3 FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu... \n", "5 自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド... \n", "7 既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita... \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra... \n", ".. ... \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n", "739 切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験 \n", "760 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... \n", "762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 \n", "772 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... \n", "\n", " TargetJ \\\n", "0 以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌 \n", "3 切除不能進行・再発の胃または食道胃接合部腺癌 \n", "5 多発性骨髄腫 \n", "7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n", ".. ... \n", "729 乳がん \n", "739 膵癌 \n", "760 悪性黒色腫 \n", "762 肝細胞癌 \n", "772 進行性悪性黒色腫 \n", "\n", " Target \\\n", "0 以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌 \n", "3 切除不能進行・再発の胃または食道胃接合部腺癌 \n", "5 多発性骨髄腫 \n", "7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n", ".. ... \n", "729 乳がん \n", "739 膵癌 \n", "760 悪性黒色腫 \n", "762 肝細胞癌 \n", "772 進行性悪性黒色腫 \n", "\n", " TargetEnglish \\\n", "0 Non-Small Cell Lung Cancer (NSCLC) Pancreatic ... \n", "3 Advanced Gastric or Gastroesophageal Junction ... \n", "5 Multiple Myeloma \n", "7 Head and neck squamous cell carcinoma/Non-smal... \n", "9 Stage II-III HER2-Amplified or HER2-Mutant Non... \n", ".. ... \n", "729 Breast cancer \n", "739 Pancreatic cancer \n", "760 malignant melanoma \n", "762 Hepatocellular carcinoma \n", "772 advanced melanoma \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "0 Treatment 1-2 NaN ... \n", "3 フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又... 2 NaN ... \n", "5 自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ... 3 NaN ... \n", "7 既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形... 2 NaN ... \n", "9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... 2 NaN ... \n", ".. ... ... ... ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "739 切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。 1-2 NaN ... \n", "760 第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN ... \n", "762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 1 NaN ... \n", "772 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "0 treatment purpose 1. Participant must be 18 years or more, or th... \n", "3 treatment purpose 1) Histologically documented gastric or GEJ ad... \n", "5 treatment purpose 1. Is at least 18 or the legal age of consent ... \n", "7 treatment purpose Cohort 1: Head and neck squamous cell carcinom... \n", "9 treatment purpose 1. Signed informed consent form 2. Age >= 18 y... \n", ".. ... ... \n", "729 treatment purpose 1)Patients with inop... \n", "739 treatment purpose The patients with pancreatic tumors must meet ... \n", "760 treatment purpose (Phase 1) 1) Histologically confirmed malignan... \n", "762 treatment purpose 1) Histologically or cytologically confirmed h... \n", "772 treatment purpose Inclusion criteria Patients meeting all of the... \n", "\n", " Exclusion Criteria \\\n", "0 1. Any significant laboratory finding or any s... \n", "3 1) Prior treatment with taxanes 2) Prior treat... \n", "5 Participants are excluded from the study if an... \n", "7 - Prior treatment with a monomethyl auristatin... \n", "9 1. NSCLC that is clinically T4 by virtue of me... \n", ".. ... \n", "729 1)Patients correspond to either of the followi... \n", "739 1) Patients with the following complications: ... \n", "760 (Phase 1 and 2) 1) Patients who have brain and... \n", "762 1) CNS metastases that are symptomatic or requ... \n", "772 Exclusion criteria Patients meeting any of the... \n", "\n", " Age Minimum Age Maximum Gender \\\n", "0 18age old over No limit Both \n", "3 18age old over No limit Both \n", "5 18age old over No limit Both \n", "7 18age old over No limit Both \n", "9 18age old over No limit Both \n", ".. ... ... ... \n", "729 20age old over No limit Female \n", "739 20age old over No limit Both \n", "760 20age old over No limit Both \n", "762 20age 0month 0week old over No limit Both \n", "772 20age old over 86age old not Both \n", "\n", " Discontinuation Criteria Keyword \\\n", "0 NaN NaN \n", "3 NaN NaN \n", "5 NaN NaN \n", "7 NaN NaN \n", "9 NaN NaN \n", ".. ... ... \n", "729 NaN Breast cancer \n", "739 NaN Pancreatic ductal carcinoma, unresectable \n", "760 NaN malignamt melanoma, advanced stage \n", "762 NaN Cancer peptide vaccine \n", "772 NaN advanced melanoma \n", "\n", " Intervention(s) \\\n", "0 AZD0022 \n", "3 - Bemarituzumab (15mg/kg, intravenous, Day1, 1... \n", "5 Arm A: Belantamab Mafodotin is intraveniously ... \n", "7 Experimental Arm - Disitamab vedotin 1.5 mg/kg... \n", "9 The study drug will be administered as an IV i... \n", ".. ... \n", "729 For the target tumor, the dose settled at each... \n", "739 Intratumoral administration of oncolytic virus \n", "760 Test drug (T-hIL12) will be administered into ... \n", "762 Reconstitute two kinds of cancer peptide vacci... \n", "772 combination therapy of intracutaneous GEN0101 ... \n", "\n", " TargetWord \n", "0 [Non-Small Cell Lung Cancer (Nsclc) Pancreatic... \n", "3 [Advanced Gastric, Gastroesophageal Junction C... \n", "5 [Multiple Myeloma] \n", "7 [Head, Neck Squamous Cell Carcinoma/Non-Small ... \n", "9 [Stage Ii-Iii Her2-Amplified, Her2-Mutant Non-... \n", ".. ... \n", "729 [Breast Cancer] \n", "739 [Pancreatic Cancer] \n", "760 [Malignant Melanoma] \n", "762 [Hepatocellular Carcinoma] \n", "772 [Advanced Melanoma] \n", "\n", "[427 rows x 40 columns]" ] }, "execution_count": 79, "metadata": {}, "output_type": "execute_result" } ], "source": [ "basedf.dropna(subset=['TargetEnglish'])" ] }, { "cell_type": "code", "execution_count": 80, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "391 [Relapsed/Refract, Y Locally Advanced, Metasta...\n", "Name: TargetWord, dtype: object\n", "391 Relapsed/Refractory Locally Advanced or Metast...\n", "Name: TargetEnglish, dtype: object\n", "391 Dose Escalation and Expansion Cohorts 1. Women...\n", "Name: Exclusion Criteria, dtype: object\n" ] } ], "source": [ "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['TargetWord'])\n", "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['TargetEnglish'])\n", "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['Exclusion Criteria'])" ] }, { "cell_type": "code", "execution_count": 81, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "['Relapsed/Refract', 'Y Locally Advanced', 'Metastatic Breast Cancer', 'Triple Negative', 'Breast Cancer']\n", "Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer\n", "Dose Escalation and Expansion Cohorts 1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) not using adequate birth control see Appendix H: Forms of contraception. 2. Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery, radiotherapy or requiring corticosteroids to control symptoms, or patients with symptoms suggesting CNS involvement for which treatment is required. 3. Patients with primary brain tumors. 4. Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma. 5. Patients with any of the following hematologic abnormalities at baseline. (Patients may have received a red blood cell product transfusion prior to study, if clinically warranted.): -Absolute neutrophil count (ANC) < 1,500 per mm3 -Platelet count < 100,000 per mm3 -Hemoglobin < 8.0 gm/dL 6. Patients with any of the following serum chemistry abnormalities at baseline: -Total bilirubin >= 1.5 times the ULN for the institution value -AST or ALT >= 3 times the ULN for the institution value (>= 5 times if due to hepatic involvement by tumor) -Creatinine >= 1.5 times ULN for the institution value (or a calculated creatinine clearance < 60 mL/min/1.73 m2) 7. Patients with a significant active cardiovascular disease or condition, including: -Congestive heart failure (CHF)requiring therapy -Need for antiarrhythmic medical therapy for a ventricular arrhythmia -Severe conduction disturbance -Unstable angina pectoris requiring therapy -QTc interval > 450 msec (males) or > 470 msec (females) -QTc interval =< 300 msec -History of congenital long QT syndrome or congenital short QT syndrome -LVEF < 50% as measured by echocardiography or MUGA scan -Uncontrolled hypertension (per the Investigator's discretion) -Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria (see APPENDIX C: New York Heart Association's Functional Criteria). -Myocardial infarction (MI) within 6 months prior to first study drug administration 8. Patients with a known or suspected hypersensitivity to any of the components of OTS167. 9. Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). 10. Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38 degrees within 1 week prior to first study drug administration. 11. Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration. 12. Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug. 13. Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies. 14. Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements. 15. Any anti-neoplastic agent or monoclonal antibody therapy for the primary malignancy (standard or experimental) within 2 weeks prior to first study drug administration. 16. Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment. If acute symptoms of radiation have fully resolved, the extent and timing of radiotherapy for eligibility can be discussed between Investigator and Sponsor. 17. Patients requiring surgery for the primary or metastatic primary malignancy. 18. Herbal preparations or related over the counter (OTC) preparations/supplements containing herbal ingredients within 1 week prior to first study drug administration and during study. 19. Systemic hormonal therapy which is not related to breast cancer treatment (standard or experimental) within 1 week prior to first study drug administration and during study. The following therapies are allowed: -Hormonal therapy (e.g., Megace) for appetite stimulation -Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations -Oral replacement glucocorticoid therapy for adrenal insufficiency -Low-dose maintenance steroid therapy for other conditions (excluding steroid tapers for brain edema/metastases/radiation) -Hormonal contraceptive therapy (for WOCBP must be combined with non-hormonal contraceptive equivalent to a double-barrier method) 20. Any other investigational treatments during study. This includes participation in any medical device or therapeutic intervention clinical trials. Dose expansion Cohort for TNBC 21. Patients with only lesions that cannot be safely accessed for biopsy.\n" ] } ], "source": [ "# 値を直接取得して表示\n", "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'TargetWord'].values[0])\n", "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'TargetEnglish'].values[0])\n", "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'Exclusion Criteria'].values[0])\n" ] }, { "cell_type": "code", "execution_count": 82, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n", " warnings.warn(\n" ] } ], "source": [ "# モデルのロード\n", "model = SentenceTransformer('pritamdeka/S-PubMedBert-MS-MARCO')" ] }, { "cell_type": "code", "execution_count": 89, "metadata": {}, "outputs": [], "source": [ "# クエリ\n", "#query = \"Triple negative breast cancer\"\n", "query = \"breast cancer\"\n", "#query = \"glioma\"\n", "threshold = 0.925\n", "# クエリをベクトル化\n", "query_vec = model.encode(query, convert_to_tensor=True)\n" ] }, { "cell_type": "code", "execution_count": 90, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
31jRCT2061240081NCT06393374NaN術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...トリプルネガティブ乳癌トリプルネガティブ乳癌Triple negative breast cancer術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...3NaN...treatment purpose-Has centrally confirmed TNBC, as defined by t...-Has a known germline breast cancer gene (BRCA...18age old overNo limitBothNaNNaN-Arm 1: MK-2870 4mg/kg intravenous (IV) every ...[Triple Negative, Breast Cancer]
157jRCT2052240059NaNNaN遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...乳がん乳がんBreast cancerHSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...2NaN...diagnostic purpose1. Histologically confirmed invasive breast ca...1. History of other malignancy within the last...20age old overNo limitFemaleNaNNaNOmitting breast surgery after preoperative che...[Breast Cancer]
170jRCT2031240096NCT06380751NaN本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...進行乳癌進行乳癌Advanced Breast CancerTreatment3NaN...treatment purpose- Adult females, pre/peri-menopausal and/or po...- Participants with history of MDS/AML or with...18age old overNo limitBothNaNNaNExperimental: Arm 1: saruparib (AZD5305) plus ...[Advanced Breast Cancer]
215jRCT2031230723NCT06112379NaN未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...乳癌乳癌Breast Cancer未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...3NaN...treatment purpose1. Participant must be >= 18 years at the time...1. As judged by the investigator, any evidence...18age old overNo limitBothNaNNaN- Experimental arm: Dato-DXd plus durvalumab n...[Breast Cancer]
240jRCT2061230102NCT06103864NaNProgrammed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...乳癌乳癌Breast CancerPD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...3NaN...treatment purposeHistologically or cytologically documented loc...As judged by investigator, severe or uncontrol...18age old overNo limitBothNaNNaNArm 1: Dato-DXd + durvalumab Arm 2: Investigat...[Breast Cancer]
307jRCT2061230074NCT05952557NaN根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men; 18 years or more at the time ...- Inoperable locally advanced or metastatic br...18age old overNo limitNaNNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
351jRCT2031230279NCT05862285NaNGENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...癌癌Cancer本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...3NaN...treatment purpose- Eligible for continuing Roche IMP-based ther...- Meet any of the study treatment discontinuat...18age old overNo limitBothNaNNaNIpatasertib: Ipatasertib will be administered ...[Cancer]
388jRCT2031230109NCT05514054NaNEMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...乳癌乳癌Breast Neoplasms早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験3NaN...treatment purpose-Have a diagnosis of ER+, HER2- early-stage, r...-Have any evidence of metastatic disease (incl...18age old overNo limitBothNaNNaN-Drug: Imlunestrant Administered orally. Other...[Breast Neoplasms]
391jRCT2031230090NaNNaNMELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がんRelapsed/Refractory Locally Advanced or Metast...再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...1NaN...treatment purposeDose Escalation and Dose Expansion Cohorts 1. ...Dose Escalation and Expansion Cohorts 1. Women...18age old overNo limitFemaleNaNNaNThis is a Phase I dose escalation/expansion mu...[Relapsed/Refract, Y Locally Advanced, Metasta...
392jRCT2031230096NCT05774951NaN根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men, greater than or equal to 18 y...- Inoperable locally advanced or metastatic br...18age old overNo limitBothNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
402jRCT2061230009NCT05485766NaNgBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...トリプルネガティブ乳がんトリプルネガティブ乳がんTriple Negative Breast Neoplasms術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...2NaN...treatment purpose1)Male/female subjects who are at least 18 yea...1) Subjects who has a positive urine pregnancy...18age old exceedNo limitBothNaNTriple Negative Breast Cancer, Breast Neoplasm...Drug: Pembrolizumab 200 mg fixed dose, IV, eve...[Triple Negative, Breast Neoplasms]
463jRCT2061220087NCT05629585NaN術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...乳癌乳癌Breast Cancer術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...3NaN...treatment purposeParticipant must be >= 18 years at the time of...Stage IV (metastatic) TNBC. History of prior i...18age old over130age old underBothNaNNaNArm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...[Breast Cancer]
515jRCT2031220276NCT05307705NaNPIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...乳がん乳がんBreast CancerLOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...1NaN...treatment purpose-Have advanced breast cancer or another solid ...-Medical Conditions -Colorectal cancer -Endome...18age old overNo limitBothNaNNaN-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...[Breast Cancer]
590jRCT2031210585NCT05123482NaN進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...乳癌、胆道癌、卵巣癌、子宮内膜癌乳癌、胆道癌、卵巣癌、子宮内膜癌Breast Cancer, Biliary Tract Carcinoma, Ovaria...進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究1-2NaN...treatment purpose- Age18 years or more - Relapsed/metastatic so...- Treatment with any of the following: 1. Nitr...18age old overNo limitBothNaNNaNSub-study1 AZD8205 Monotherapy AZD8205 is an a...[Breast Cancer, Biliary Tract Carcinoma, Ovari...
593jRCT2031210560NCT05061823NaN複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...固形癌固形癌Cancer本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...3NaN...treatment purpose- Participants who are currently enrolled in a...- Participants who are pregnant or currently i...18age old overNo limitBothNaNNaNParticipants who are continuing treatment with...[Cancer]
629jRCT2052210099NaNNaN乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...乳がん乳がんBreast cancer本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...2NaN...screeningBreast cancer (including suspected) (1) One of...(1) There is trauma with bleeding on the breas...20age old overNo limitFemaleNaNNaNThe test using IGS-0001 will be performed twic...[Breast Cancer]
698jRCT2071200086NCT04640623NaN膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...膀胱癌膀胱癌Bladder Cancer試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...2NaN...treatment purpose- Histologically confirmed diagnosis of persis...- Histologically confirmed, muscle-invasive, l...18age old overNo limitBothNaNNaNTAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...[Bladder Cancer]
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast Cancer]
\n", "

18 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "31 jRCT2061240081 NCT06393374 NaN \n", "157 jRCT2052240059 NaN NaN \n", "170 jRCT2031240096 NCT06380751 NaN \n", "215 jRCT2031230723 NCT06112379 NaN \n", "240 jRCT2061230102 NCT06103864 NaN \n", "307 jRCT2061230074 NCT05952557 NaN \n", "351 jRCT2031230279 NCT05862285 NaN \n", "388 jRCT2031230109 NCT05514054 NaN \n", "391 jRCT2031230090 NaN NaN \n", "392 jRCT2031230096 NCT05774951 NaN \n", "402 jRCT2061230009 NCT05485766 NaN \n", "463 jRCT2061220087 NCT05629585 NaN \n", "515 jRCT2031220276 NCT05307705 NaN \n", "590 jRCT2031210585 NCT05123482 NaN \n", "593 jRCT2031210560 NCT05061823 NaN \n", "629 jRCT2052210099 NaN NaN \n", "698 jRCT2071200086 NCT04640623 NaN \n", "729 jRCT2031200057 NaN NaN \n", "\n", " Title \\\n", "31 術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... \n", "157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... \n", "170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... \n", "240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... \n", "307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... \n", "351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... \n", "388 EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... \n", "391 MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... \n", "392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... \n", "402 gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP... \n", "463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... \n", "515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... \n", "590 進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... \n", "593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... \n", "629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... \n", "698 膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG... \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n", "\n", " TargetJ Target \\\n", "31 トリプルネガティブ乳癌 トリプルネガティブ乳癌 \n", "157 乳がん 乳がん \n", "170 進行乳癌 進行乳癌 \n", "215 乳癌 乳癌 \n", "240 乳癌 乳癌 \n", "307 乳がん、早期乳がん 乳がん、早期乳がん \n", "351 癌 癌 \n", "388 乳癌 乳癌 \n", "391 再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん 再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん \n", "392 乳がん、早期乳がん 乳がん、早期乳がん \n", "402 トリプルネガティブ乳がん トリプルネガティブ乳がん \n", "463 乳癌 乳癌 \n", "515 乳がん 乳がん \n", "590 乳癌、胆道癌、卵巣癌、子宮内膜癌 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n", "593 固形癌 固形癌 \n", "629 乳がん 乳がん \n", "698 膀胱癌 膀胱癌 \n", "729 乳がん 乳がん \n", "\n", " TargetEnglish \\\n", "31 Triple negative breast cancer \n", "157 Breast cancer \n", "170 Advanced Breast Cancer \n", "215 Breast Cancer \n", "240 Breast Cancer \n", "307 Breast Cancer, Early Breast Cancer \n", "351 Cancer \n", "388 Breast Neoplasms \n", "391 Relapsed/Refractory Locally Advanced or Metast... \n", "392 Breast Cancer, Early Breast Cancer \n", "402 Triple Negative Breast Neoplasms \n", "463 Breast Cancer \n", "515 Breast Cancer \n", "590 Breast Cancer, Biliary Tract Carcinoma, Ovaria... \n", "593 Cancer \n", "629 Breast cancer \n", "698 Bladder Cancer \n", "729 Breast cancer \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "31 術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... 3 NaN ... \n", "157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n", "170 Treatment 3 NaN ... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n", "240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n", "307 Treatment 3 NaN ... \n", "351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n", "388 早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 3 NaN ... \n", "391 再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... 1 NaN ... \n", "392 Treatment 3 NaN ... \n", "402 術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク... 2 NaN ... \n", "463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n", "515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n", "590 進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 1-2 NaN ... \n", "593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n", "629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n", "698 試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT... 2 NaN ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "31 treatment purpose -Has centrally confirmed TNBC, as defined by t... \n", "157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n", "170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n", "215 treatment purpose 1. Participant must be >= 18 years at the time... \n", "240 treatment purpose Histologically or cytologically documented loc... \n", "307 treatment purpose - Women and Men; 18 years or more at the time ... \n", "351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n", "388 treatment purpose -Have a diagnosis of ER+, HER2- early-stage, r... \n", "391 treatment purpose Dose Escalation and Dose Expansion Cohorts 1. ... \n", "392 treatment purpose - Women and Men, greater than or equal to 18 y... \n", "402 treatment purpose 1)Male/female subjects who are at least 18 yea... \n", "463 treatment purpose Participant must be >= 18 years at the time of... \n", "515 treatment purpose -Have advanced breast cancer or another solid ... \n", "590 treatment purpose - Age18 years or more - Relapsed/metastatic so... \n", "593 treatment purpose - Participants who are currently enrolled in a... \n", "629 screening Breast cancer (including suspected) (1) One of... \n", "698 treatment purpose - Histologically confirmed diagnosis of persis... \n", "729 treatment purpose 1)Patients with inop... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "31 -Has a known germline breast cancer gene (BRCA... 18age old over \n", "157 1. History of other malignancy within the last... 20age old over \n", "170 - Participants with history of MDS/AML or with... 18age old over \n", "215 1. As judged by the investigator, any evidence... 18age old over \n", "240 As judged by investigator, severe or uncontrol... 18age old over \n", "307 - Inoperable locally advanced or metastatic br... 18age old over \n", "351 - Meet any of the study treatment discontinuat... 18age old over \n", "388 -Have any evidence of metastatic disease (incl... 18age old over \n", "391 Dose Escalation and Expansion Cohorts 1. Women... 18age old over \n", "392 - Inoperable locally advanced or metastatic br... 18age old over \n", "402 1) Subjects who has a positive urine pregnancy... 18age old exceed \n", "463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n", "515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n", "590 - Treatment with any of the following: 1. Nitr... 18age old over \n", "593 - Participants who are pregnant or currently i... 18age old over \n", "629 (1) There is trauma with bleeding on the breas... 20age old over \n", "698 - Histologically confirmed, muscle-invasive, l... 18age old over \n", "729 1)Patients correspond to either of the followi... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "31 No limit Both NaN \n", "157 No limit Female NaN \n", "170 No limit Both NaN \n", "215 No limit Both NaN \n", "240 No limit Both NaN \n", "307 No limit NaN NaN \n", "351 No limit Both NaN \n", "388 No limit Both NaN \n", "391 No limit Female NaN \n", "392 No limit Both NaN \n", "402 No limit Both NaN \n", "463 130age old under Both NaN \n", "515 No limit Both NaN \n", "590 No limit Both NaN \n", "593 No limit Both NaN \n", "629 No limit Female NaN \n", "698 No limit Both NaN \n", "729 No limit Female NaN \n", "\n", " Keyword \\\n", "31 NaN \n", "157 NaN \n", "170 NaN \n", "215 NaN \n", "240 NaN \n", "307 NaN \n", "351 NaN \n", "388 NaN \n", "391 NaN \n", "392 NaN \n", "402 Triple Negative Breast Cancer, Breast Neoplasm... \n", "463 NaN \n", "515 NaN \n", "590 NaN \n", "593 NaN \n", "629 NaN \n", "698 NaN \n", "729 Breast cancer \n", "\n", " Intervention(s) \\\n", "31 -Arm 1: MK-2870 4mg/kg intravenous (IV) every ... \n", "157 Omitting breast surgery after preoperative che... \n", "170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n", "215 - Experimental arm: Dato-DXd plus durvalumab n... \n", "240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n", "307 arm A: continue with SoC ET as directed by inv... \n", "351 Ipatasertib: Ipatasertib will be administered ... \n", "388 -Drug: Imlunestrant Administered orally. Other... \n", "391 This is a Phase I dose escalation/expansion mu... \n", "392 arm A: continue with SoC ET as directed by inv... \n", "402 Drug: Pembrolizumab 200 mg fixed dose, IV, eve... \n", "463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n", "515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n", "590 Sub-study1 AZD8205 Monotherapy AZD8205 is an a... \n", "593 Participants who are continuing treatment with... \n", "629 The test using IGS-0001 will be performed twic... \n", "698 TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-... \n", "729 For the target tumor, the dose settled at each... \n", "\n", " TargetWord \n", "31 [Triple Negative, Breast Cancer] \n", "157 [Breast Cancer] \n", "170 [Advanced Breast Cancer] \n", "215 [Breast Cancer] \n", "240 [Breast Cancer] \n", "307 [Breast Cancer, Early Breast Cancer] \n", "351 [Cancer] \n", "388 [Breast Neoplasms] \n", "391 [Relapsed/Refract, Y Locally Advanced, Metasta... \n", "392 [Breast Cancer, Early Breast Cancer] \n", "402 [Triple Negative, Breast Neoplasms] \n", "463 [Breast Cancer] \n", "515 [Breast Cancer] \n", "590 [Breast Cancer, Biliary Tract Carcinoma, Ovari... \n", "593 [Cancer] \n", "629 [Breast Cancer] \n", "698 [Bladder Cancer] \n", "729 [Breast Cancer] \n", "\n", "[18 rows x 40 columns]" ] }, "execution_count": 90, "metadata": {}, "output_type": "execute_result" } ], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]\n", "matched_df" ] }, { "cell_type": "code", "execution_count": 92, "metadata": {}, "outputs": [ { "ename": "TypeError", "evalue": "list indices must be integers or slices, not list", "output_type": "error", "traceback": [ "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m", "\u001b[0;31mTypeError\u001b[0m Traceback (most recent call last)", "Cell \u001b[0;32mIn[92], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mcosine_scores_list\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43mmatched_indices\u001b[49m\u001b[43m]\u001b[49m\n", "\u001b[0;31mTypeError\u001b[0m: list indices must be integers or slices, not list" ] } ], "source": [ "cosine_scores_list [matched_indices]" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] }, { "cell_type": "code", "execution_count": 86, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
31jRCT2061240081NCT06393374NaN術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...トリプルネガティブ乳癌トリプルネガティブ乳癌Triple negative breast cancer術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...3NaN...treatment purpose-Has centrally confirmed TNBC, as defined by t...-Has a known germline breast cancer gene (BRCA...18age old overNo limitBothNaNNaN-Arm 1: MK-2870 4mg/kg intravenous (IV) every ...[Triple Negative, Breast Cancer]
157jRCT2052240059NaNNaN遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...乳がん乳がんBreast cancerHSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...2NaN...diagnostic purpose1. Histologically confirmed invasive breast ca...1. History of other malignancy within the last...20age old overNo limitFemaleNaNNaNOmitting breast surgery after preoperative che...[Breast Cancer]
215jRCT2031230723NCT06112379NaN未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...乳癌乳癌Breast Cancer未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...3NaN...treatment purpose1. Participant must be >= 18 years at the time...1. As judged by the investigator, any evidence...18age old overNo limitBothNaNNaN- Experimental arm: Dato-DXd plus durvalumab n...[Breast Cancer]
240jRCT2061230102NCT06103864NaNProgrammed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...乳癌乳癌Breast CancerPD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...3NaN...treatment purposeHistologically or cytologically documented loc...As judged by investigator, severe or uncontrol...18age old overNo limitBothNaNNaNArm 1: Dato-DXd + durvalumab Arm 2: Investigat...[Breast Cancer]
307jRCT2061230074NCT05952557NaN根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men; 18 years or more at the time ...- Inoperable locally advanced or metastatic br...18age old overNo limitNaNNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
388jRCT2031230109NCT05514054NaNEMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...乳癌乳癌Breast Neoplasms早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験3NaN...treatment purpose-Have a diagnosis of ER+, HER2- early-stage, r...-Have any evidence of metastatic disease (incl...18age old overNo limitBothNaNNaN-Drug: Imlunestrant Administered orally. Other...[Breast Neoplasms]
391jRCT2031230090NaNNaNMELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がんRelapsed/Refractory Locally Advanced or Metast...再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...1NaN...treatment purposeDose Escalation and Dose Expansion Cohorts 1. ...Dose Escalation and Expansion Cohorts 1. Women...18age old overNo limitFemaleNaNNaNThis is a Phase I dose escalation/expansion mu...[Relapsed/Refract, Y Locally Advanced, Metasta...
392jRCT2031230096NCT05774951NaN根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men, greater than or equal to 18 y...- Inoperable locally advanced or metastatic br...18age old overNo limitBothNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
402jRCT2061230009NCT05485766NaNgBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...トリプルネガティブ乳がんトリプルネガティブ乳がんTriple Negative Breast Neoplasms術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...2NaN...treatment purpose1)Male/female subjects who are at least 18 yea...1) Subjects who has a positive urine pregnancy...18age old exceedNo limitBothNaNTriple Negative Breast Cancer, Breast Neoplasm...Drug: Pembrolizumab 200 mg fixed dose, IV, eve...[Triple Negative, Breast Neoplasms]
463jRCT2061220087NCT05629585NaN術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...乳癌乳癌Breast Cancer術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...3NaN...treatment purposeParticipant must be >= 18 years at the time of...Stage IV (metastatic) TNBC. History of prior i...18age old over130age old underBothNaNNaNArm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...[Breast Cancer]
515jRCT2031220276NCT05307705NaNPIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...乳がん乳がんBreast CancerLOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...1NaN...treatment purpose-Have advanced breast cancer or another solid ...-Medical Conditions -Colorectal cancer -Endome...18age old overNo limitBothNaNNaN-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...[Breast Cancer]
590jRCT2031210585NCT05123482NaN進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...乳癌、胆道癌、卵巣癌、子宮内膜癌乳癌、胆道癌、卵巣癌、子宮内膜癌Breast Cancer, Biliary Tract Carcinoma, Ovaria...進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究1-2NaN...treatment purpose- Age18 years or more - Relapsed/metastatic so...- Treatment with any of the following: 1. Nitr...18age old overNo limitBothNaNNaNSub-study1 AZD8205 Monotherapy AZD8205 is an a...[Breast Cancer, Biliary Tract Carcinoma, Ovari...
629jRCT2052210099NaNNaN乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...乳がん乳がんBreast cancer本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...2NaN...screeningBreast cancer (including suspected) (1) One of...(1) There is trauma with bleeding on the breas...20age old overNo limitFemaleNaNNaNThe test using IGS-0001 will be performed twic...[Breast Cancer]
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast Cancer]
\n", "

14 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "31 jRCT2061240081 NCT06393374 NaN \n", "157 jRCT2052240059 NaN NaN \n", "215 jRCT2031230723 NCT06112379 NaN \n", "240 jRCT2061230102 NCT06103864 NaN \n", "307 jRCT2061230074 NCT05952557 NaN \n", "388 jRCT2031230109 NCT05514054 NaN \n", "391 jRCT2031230090 NaN NaN \n", "392 jRCT2031230096 NCT05774951 NaN \n", "402 jRCT2061230009 NCT05485766 NaN \n", "463 jRCT2061220087 NCT05629585 NaN \n", "515 jRCT2031220276 NCT05307705 NaN \n", "590 jRCT2031210585 NCT05123482 NaN \n", "629 jRCT2052210099 NaN NaN \n", "729 jRCT2031200057 NaN NaN \n", "\n", " Title \\\n", "31 術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... \n", "157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... \n", "240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... \n", "307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... \n", "388 EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... \n", "391 MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... \n", "392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... \n", "402 gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP... \n", "463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... \n", "515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... \n", "590 進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... \n", "629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n", "\n", " TargetJ Target \\\n", "31 トリプルネガティブ乳癌 トリプルネガティブ乳癌 \n", "157 乳がん 乳がん \n", "215 乳癌 乳癌 \n", "240 乳癌 乳癌 \n", "307 乳がん、早期乳がん 乳がん、早期乳がん \n", "388 乳癌 乳癌 \n", "391 再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん 再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん \n", "392 乳がん、早期乳がん 乳がん、早期乳がん \n", "402 トリプルネガティブ乳がん トリプルネガティブ乳がん \n", "463 乳癌 乳癌 \n", "515 乳がん 乳がん \n", "590 乳癌、胆道癌、卵巣癌、子宮内膜癌 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n", "629 乳がん 乳がん \n", "729 乳がん 乳がん \n", "\n", " TargetEnglish \\\n", "31 Triple negative breast cancer \n", "157 Breast cancer \n", "215 Breast Cancer \n", "240 Breast Cancer \n", "307 Breast Cancer, Early Breast Cancer \n", "388 Breast Neoplasms \n", "391 Relapsed/Refractory Locally Advanced or Metast... \n", "392 Breast Cancer, Early Breast Cancer \n", "402 Triple Negative Breast Neoplasms \n", "463 Breast Cancer \n", "515 Breast Cancer \n", "590 Breast Cancer, Biliary Tract Carcinoma, Ovaria... \n", "629 Breast cancer \n", "729 Breast cancer \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "31 術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... 3 NaN ... \n", "157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n", "240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n", "307 Treatment 3 NaN ... \n", "388 早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 3 NaN ... \n", "391 再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... 1 NaN ... \n", "392 Treatment 3 NaN ... \n", "402 術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク... 2 NaN ... \n", "463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n", "515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n", "590 進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 1-2 NaN ... \n", "629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "31 treatment purpose -Has centrally confirmed TNBC, as defined by t... \n", "157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n", "215 treatment purpose 1. Participant must be >= 18 years at the time... \n", "240 treatment purpose Histologically or cytologically documented loc... \n", "307 treatment purpose - Women and Men; 18 years or more at the time ... \n", "388 treatment purpose -Have a diagnosis of ER+, HER2- early-stage, r... \n", "391 treatment purpose Dose Escalation and Dose Expansion Cohorts 1. ... \n", "392 treatment purpose - Women and Men, greater than or equal to 18 y... \n", "402 treatment purpose 1)Male/female subjects who are at least 18 yea... \n", "463 treatment purpose Participant must be >= 18 years at the time of... \n", "515 treatment purpose -Have advanced breast cancer or another solid ... \n", "590 treatment purpose - Age18 years or more - Relapsed/metastatic so... \n", "629 screening Breast cancer (including suspected) (1) One of... \n", "729 treatment purpose 1)Patients with inop... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "31 -Has a known germline breast cancer gene (BRCA... 18age old over \n", "157 1. History of other malignancy within the last... 20age old over \n", "215 1. As judged by the investigator, any evidence... 18age old over \n", "240 As judged by investigator, severe or uncontrol... 18age old over \n", "307 - Inoperable locally advanced or metastatic br... 18age old over \n", "388 -Have any evidence of metastatic disease (incl... 18age old over \n", "391 Dose Escalation and Expansion Cohorts 1. Women... 18age old over \n", "392 - Inoperable locally advanced or metastatic br... 18age old over \n", "402 1) Subjects who has a positive urine pregnancy... 18age old exceed \n", "463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n", "515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n", "590 - Treatment with any of the following: 1. Nitr... 18age old over \n", "629 (1) There is trauma with bleeding on the breas... 20age old over \n", "729 1)Patients correspond to either of the followi... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "31 No limit Both NaN \n", "157 No limit Female NaN \n", "215 No limit Both NaN \n", "240 No limit Both NaN \n", "307 No limit NaN NaN \n", "388 No limit Both NaN \n", "391 No limit Female NaN \n", "392 No limit Both NaN \n", "402 No limit Both NaN \n", "463 130age old under Both NaN \n", "515 No limit Both NaN \n", "590 No limit Both NaN \n", "629 No limit Female NaN \n", "729 No limit Female NaN \n", "\n", " Keyword \\\n", "31 NaN \n", "157 NaN \n", "215 NaN \n", "240 NaN \n", "307 NaN \n", "388 NaN \n", "391 NaN \n", "392 NaN \n", "402 Triple Negative Breast Cancer, Breast Neoplasm... \n", "463 NaN \n", "515 NaN \n", "590 NaN \n", "629 NaN \n", "729 Breast cancer \n", "\n", " Intervention(s) \\\n", "31 -Arm 1: MK-2870 4mg/kg intravenous (IV) every ... \n", "157 Omitting breast surgery after preoperative che... \n", "215 - Experimental arm: Dato-DXd plus durvalumab n... \n", "240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n", "307 arm A: continue with SoC ET as directed by inv... \n", "388 -Drug: Imlunestrant Administered orally. Other... \n", "391 This is a Phase I dose escalation/expansion mu... \n", "392 arm A: continue with SoC ET as directed by inv... \n", "402 Drug: Pembrolizumab 200 mg fixed dose, IV, eve... \n", "463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n", "515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n", "590 Sub-study1 AZD8205 Monotherapy AZD8205 is an a... \n", "629 The test using IGS-0001 will be performed twic... \n", "729 For the target tumor, the dose settled at each... \n", "\n", " TargetWord \n", "31 [Triple Negative, Breast Cancer] \n", "157 [Breast Cancer] \n", "215 [Breast Cancer] \n", "240 [Breast Cancer] \n", "307 [Breast Cancer, Early Breast Cancer] \n", "388 [Breast Neoplasms] \n", "391 [Relapsed/Refract, Y Locally Advanced, Metasta... \n", "392 [Breast Cancer, Early Breast Cancer] \n", "402 [Triple Negative, Breast Neoplasms] \n", "463 [Breast Cancer] \n", "515 [Breast Cancer] \n", "590 [Breast Cancer, Biliary Tract Carcinoma, Ovari... \n", "629 [Breast Cancer] \n", "729 [Breast Cancer] \n", "\n", "[14 rows x 40 columns]" ] }, "execution_count": 86, "metadata": {}, "output_type": "execute_result" } ], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]\n", "matched_df" ] }, { "cell_type": "code", "execution_count": 14, "metadata": {}, "outputs": [], "source": [ "# 全データのターゲット列をベクトル化\n", "target_list = basedf['TargetEnglish'].tolist()\n", "target_vecs = model.encode(target_list, convert_to_tensor=True)\n", "# コサイン類似度を計算\n", "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()" ] }, { "cell_type": "code", "execution_count": 15, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
157jRCT2052240059NaNNaN遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...乳がん乳がんBreast cancerHSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...2NaN...diagnostic purpose1. Histologically confirmed invasive breast ca...1. History of other malignancy within the last...20age old overNo limitFemaleNaNNaNOmitting breast surgery after preoperative che...[Breast cancer]
170jRCT2031240096NCT06380751NaN本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...進行乳癌進行乳癌Advanced Breast CancerTreatment3NaN...treatment purpose- Adult females, pre/peri-menopausal and/or po...- Participants with history of MDS/AML or with...18age old overNo limitBothNaNNaNExperimental: Arm 1: saruparib (AZD5305) plus ...[Advanced Breast Cancer]
215jRCT2031230723NCT06112379NaN未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...乳癌乳癌Breast Cancer未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...3NaN...treatment purpose1. Participant must be >= 18 years at the time...1. As judged by the investigator, any evidence...18age old overNo limitBothNaNNaN- Experimental arm: Dato-DXd plus durvalumab n...[Breast Cancer]
240jRCT2061230102NCT06103864NaNProgrammed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...乳癌乳癌Breast CancerPD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...3NaN...treatment purposeHistologically or cytologically documented loc...As judged by investigator, severe or uncontrol...18age old overNo limitBothNaNNaNArm 1: Dato-DXd + durvalumab Arm 2: Investigat...[Breast Cancer]
307jRCT2061230074NCT05952557NaN根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men; 18 years or more at the time ...- Inoperable locally advanced or metastatic br...18age old overNo limitNaNNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
342jRCT2051230094NCT05794906NaN前立腺癌の高リスク生化学的再発（BCR）患者を対象としたアンドロゲン遮断療法（ADT）を併用...前立腺癌前立腺癌prostate cancerBAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ...3NaN...treatment purpose- Histologically or cytologically confirmed ad...- Pathological finding consistent with small c...18age old overNo limitMaleNaNNaNDrug: Darolutamide (BAY1841788, Nubeqa) Coated...[prostate cancer]
351jRCT2031230279NCT05862285NaNGENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...癌癌Cancer本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...3NaN...treatment purpose- Eligible for continuing Roche IMP-based ther...- Meet any of the study treatment discontinuat...18age old overNo limitBothNaNNaNIpatasertib: Ipatasertib will be administered ...[Cancer]
388jRCT2031230109NCT05514054NaNEMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...乳癌乳癌Breast Neoplasms早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験3NaN...treatment purpose-Have a diagnosis of ER+, HER2- early-stage, r...-Have any evidence of metastatic disease (incl...18age old overNo limitBothNaNNaN-Drug: Imlunestrant Administered orally. Other...[Breast Neoplasms]
392jRCT2031230096NCT05774951NaN根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...乳がん、早期乳がん乳がん、早期乳がんBreast Cancer, Early Breast CancerTreatment3NaN...treatment purpose- Women and Men, greater than or equal to 18 y...- Inoperable locally advanced or metastatic br...18age old overNo limitBothNaNNaNarm A: continue with SoC ET as directed by inv...[Breast Cancer, Early Breast Cancer]
463jRCT2061220087NCT05629585NaN術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...乳癌乳癌Breast Cancer術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...3NaN...treatment purposeParticipant must be >= 18 years at the time of...Stage IV (metastatic) TNBC. History of prior i...18age old over130age old underBothNaNNaNArm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...[Breast Cancer]
515jRCT2031220276NCT05307705NaNPIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...乳がん乳がんBreast CancerLOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...1NaN...treatment purpose-Have advanced breast cancer or another solid ...-Medical Conditions -Colorectal cancer -Endome...18age old overNo limitBothNaNNaN-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...[Breast Cancer]
593jRCT2031210560NCT05061823NaN複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...固形癌固形癌Cancer本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...3NaN...treatment purpose- Participants who are currently enrolled in a...- Participants who are pregnant or currently i...18age old overNo limitBothNaNNaNParticipants who are continuing treatment with...[Cancer]
600jRCT2041210123NCT05114746NaN進行性PSMA陽性転移性去勢抵抗性前立腺がん（mCRPC）を有する患者を対象に177Lu-P...前立腺癌前立腺癌Prostate Cancer本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与...2NaN...treatment purpose- ECOG performance status: 1. Post-taxane popu...- Previous treatment with any of the following...20age old overNo limitMaleNaNNaNRadiation: 177Lu-PSMA-617 administered intrave...[Prostate Cancer]
629jRCT2052210099NaNNaN乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...乳がん乳がんBreast cancer本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...2NaN...screeningBreast cancer (including suspected) (1) One of...(1) There is trauma with bleeding on the breas...20age old overNo limitFemaleNaNNaNThe test using IGS-0001 will be performed twic...[Breast cancer]
691jRCT2031200384NCT04221542NaN転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性...前立腺がん前立腺がんProstate Cancer成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用...1NaN...treatment purpose- Parts 1, 2, and 5: Participants with histolo...- Pathological finding consistent with pure sm...18age old overNo limitMaleNaNNaN- Experimental: Part 1: AMG 509 Intravenous (I...[Prostate Cancer]
698jRCT2071200086NCT04640623NaN膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...膀胱癌膀胱癌Bladder Cancer試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...2NaN...treatment purpose- Histologically confirmed diagnosis of persis...- Histologically confirmed, muscle-invasive, l...18age old overNo limitBothNaNNaNTAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...[Bladder Cancer]
729jRCT2031200057NaNNaN治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験乳がん乳がんBreast cancerTDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...1NaN...treatment purpose<Disease Characteristics> 1)Patients with inop...1)Patients correspond to either of the followi...20age old overNo limitFemaleNaNBreast cancerFor the target tumor, the dose settled at each...[Breast cancer]
\n", "

17 rows × 40 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "157 jRCT2052240059 NaN NaN \n", "170 jRCT2031240096 NCT06380751 NaN \n", "215 jRCT2031230723 NCT06112379 NaN \n", "240 jRCT2061230102 NCT06103864 NaN \n", "307 jRCT2061230074 NCT05952557 NaN \n", "342 jRCT2051230094 NCT05794906 NaN \n", "351 jRCT2031230279 NCT05862285 NaN \n", "388 jRCT2031230109 NCT05514054 NaN \n", "392 jRCT2031230096 NCT05774951 NaN \n", "463 jRCT2061220087 NCT05629585 NaN \n", "515 jRCT2031220276 NCT05307705 NaN \n", "593 jRCT2031210560 NCT05061823 NaN \n", "600 jRCT2041210123 NCT05114746 NaN \n", "629 jRCT2052210099 NaN NaN \n", "691 jRCT2031200384 NCT04221542 NaN \n", "698 jRCT2071200086 NCT04640623 NaN \n", "729 jRCT2031200057 NaN NaN \n", "\n", " Title TargetJ Target \\\n", "157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... 乳がん 乳がん \n", "170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... 進行乳癌 進行乳癌 \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 乳癌 乳癌 \n", "240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... 乳癌 乳癌 \n", "307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... 乳がん、早期乳がん 乳がん、早期乳がん \n", "342 前立腺癌の高リスク生化学的再発（BCR）患者を対象としたアンドロゲン遮断療法（ADT）を併用... 前立腺癌 前立腺癌 \n", "351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... 癌 癌 \n", "388 EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... 乳癌 乳癌 \n", "392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... 乳がん、早期乳がん 乳がん、早期乳がん \n", "463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... 乳癌 乳癌 \n", "515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... 乳がん 乳がん \n", "593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... 固形癌 固形癌 \n", "600 進行性PSMA陽性転移性去勢抵抗性前立腺がん（mCRPC）を有する患者を対象に177Lu-P... 前立腺癌 前立腺癌 \n", "629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... 乳がん 乳がん \n", "691 転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性... 前立腺がん 前立腺がん \n", "698 膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG... 膀胱癌 膀胱癌 \n", "729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 乳がん 乳がん \n", "\n", " TargetEnglish \\\n", "157 Breast cancer \n", "170 Advanced Breast Cancer \n", "215 Breast Cancer \n", "240 Breast Cancer \n", "307 Breast Cancer, Early Breast Cancer \n", "342 prostate cancer \n", "351 Cancer \n", "388 Breast Neoplasms \n", "392 Breast Cancer, Early Breast Cancer \n", "463 Breast Cancer \n", "515 Breast Cancer \n", "593 Cancer \n", "600 Prostate Cancer \n", "629 Breast cancer \n", "691 Prostate Cancer \n", "698 Bladder Cancer \n", "729 Breast cancer \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n", "170 Treatment 3 NaN ... \n", "215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n", "240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n", "307 Treatment 3 NaN ... \n", "342 BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ... 3 NaN ... \n", "351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n", "388 早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 3 NaN ... \n", "392 Treatment 3 NaN ... \n", "463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n", "515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n", "593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n", "600 本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与... 2 NaN ... \n", "629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n", "691 成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用... 1 NaN ... \n", "698 試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT... 2 NaN ... \n", "729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n", "\n", " purpose Inclusion Criteria \\\n", "157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n", "170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n", "215 treatment purpose 1. Participant must be >= 18 years at the time... \n", "240 treatment purpose Histologically or cytologically documented loc... \n", "307 treatment purpose - Women and Men; 18 years or more at the time ... \n", "342 treatment purpose - Histologically or cytologically confirmed ad... \n", "351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n", "388 treatment purpose -Have a diagnosis of ER+, HER2- early-stage, r... \n", "392 treatment purpose - Women and Men, greater than or equal to 18 y... \n", "463 treatment purpose Participant must be >= 18 years at the time of... \n", "515 treatment purpose -Have advanced breast cancer or another solid ... \n", "593 treatment purpose - Participants who are currently enrolled in a... \n", "600 treatment purpose - ECOG performance status: 1. Post-taxane popu... \n", "629 screening Breast cancer (including suspected) (1) One of... \n", "691 treatment purpose - Parts 1, 2, and 5: Participants with histolo... \n", "698 treatment purpose - Histologically confirmed diagnosis of persis... \n", "729 treatment purpose 1)Patients with inop... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "157 1. History of other malignancy within the last... 20age old over \n", "170 - Participants with history of MDS/AML or with... 18age old over \n", "215 1. As judged by the investigator, any evidence... 18age old over \n", "240 As judged by investigator, severe or uncontrol... 18age old over \n", "307 - Inoperable locally advanced or metastatic br... 18age old over \n", "342 - Pathological finding consistent with small c... 18age old over \n", "351 - Meet any of the study treatment discontinuat... 18age old over \n", "388 -Have any evidence of metastatic disease (incl... 18age old over \n", "392 - Inoperable locally advanced or metastatic br... 18age old over \n", "463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n", "515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n", "593 - Participants who are pregnant or currently i... 18age old over \n", "600 - Previous treatment with any of the following... 20age old over \n", "629 (1) There is trauma with bleeding on the breas... 20age old over \n", "691 - Pathological finding consistent with pure sm... 18age old over \n", "698 - Histologically confirmed, muscle-invasive, l... 18age old over \n", "729 1)Patients correspond to either of the followi... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria Keyword \\\n", "157 No limit Female NaN NaN \n", "170 No limit Both NaN NaN \n", "215 No limit Both NaN NaN \n", "240 No limit Both NaN NaN \n", "307 No limit NaN NaN NaN \n", "342 No limit Male NaN NaN \n", "351 No limit Both NaN NaN \n", "388 No limit Both NaN NaN \n", "392 No limit Both NaN NaN \n", "463 130age old under Both NaN NaN \n", "515 No limit Both NaN NaN \n", "593 No limit Both NaN NaN \n", "600 No limit Male NaN NaN \n", "629 No limit Female NaN NaN \n", "691 No limit Male NaN NaN \n", "698 No limit Both NaN NaN \n", "729 No limit Female NaN Breast cancer \n", "\n", " Intervention(s) \\\n", "157 Omitting breast surgery after preoperative che... \n", "170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n", "215 - Experimental arm: Dato-DXd plus durvalumab n... \n", "240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n", "307 arm A: continue with SoC ET as directed by inv... \n", "342 Drug: Darolutamide (BAY1841788, Nubeqa) Coated... \n", "351 Ipatasertib: Ipatasertib will be administered ... \n", "388 -Drug: Imlunestrant Administered orally. Other... \n", "392 arm A: continue with SoC ET as directed by inv... \n", "463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n", "515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n", "593 Participants who are continuing treatment with... \n", "600 Radiation: 177Lu-PSMA-617 administered intrave... \n", "629 The test using IGS-0001 will be performed twic... \n", "691 - Experimental: Part 1: AMG 509 Intravenous (I... \n", "698 TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-... \n", "729 For the target tumor, the dose settled at each... \n", "\n", " TargetWord \n", "157 [Breast cancer] \n", "170 [Advanced Breast Cancer] \n", "215 [Breast Cancer] \n", "240 [Breast Cancer] \n", "307 [Breast Cancer, Early Breast Cancer] \n", "342 [prostate cancer] \n", "351 [Cancer] \n", "388 [Breast Neoplasms] \n", "392 [Breast Cancer, Early Breast Cancer] \n", "463 [Breast Cancer] \n", "515 [Breast Cancer] \n", "593 [Cancer] \n", "600 [Prostate Cancer] \n", "629 [Breast cancer] \n", "691 [Prostate Cancer] \n", "698 [Bladder Cancer] \n", "729 [Breast cancer] \n", "\n", "[17 rows x 40 columns]" ] }, "execution_count": 15, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n", "# 入れ子リストをフラットなリストに変換\n", "flat_indices_d = [idx[0] for idx in matched_indices_d]\n", "\n", "# 抽出\n", "matched_df_d = basedf.iloc[flat_indices_d]\n", "matched_df_d\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "markdown", "metadata": {}, "source": [ "\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }